Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against Osiris Therapeutics, Inc. ("Osiris" or the "Company") (Nasdaq: OSIR). Investors who purchased or otherwise acquired shares between May 12, 2014 and November 20, 2015, inclusive (the "Class Period") are encouraged to contact the Firm prior to the January 22, 2016 lead plaintiff motion deadline. If you purchased shares of Osiris during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at firstname.lastname@example.org. There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member. According to the complaint, the Company announced that it has determined to correct the revenue recognition for three contracts which will result in a decrease in product revenues of $1.8 million in the first quarter of 2015, a decrease in product revenues of $1.0 million in the second quarter, an increase in product revenues of $0.8 million in the third quarter of 2015 and a decrease in product revenues of $1.1 million in 2014. When the truth was revealed, shares dropped causing investors harm. If you purchased shares of Osiris during the Class Period, you have until January 22, 2016 to ask the Court to appoint you as lead plaintiff. If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at email@example.com. This press release may constitute Attorney Advertising in some jurisdictions.